Skip to main content
Log in

ACE Inhibitor in the Treatment of Cutaneous and Lymphatic Sarcoidosis

  • Case Reports
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Angiotensin-converting enzyme is used as a marker for sarcoid activity. We describe a case of remission of cutaneous and lymphatic sarcoidosis in a patient treated with an ACE inhibitor for congestive heart failure and hypertension; the remission has continued over 4 years of follow-up. Because this is a report of only one case, there is a possibility of sampling error. Whether the patient’s remission in this case was a serendipitous spontaneous remission that happened to occur during ACE inhibitor therapy or whether ACE inhibitor therapy can play a role in the treatment of sarcoidosis needs to be determined in a large clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Leiberman J. Evaluation of serum angiotensin converting enzyme levels in sarcoidosis. Am J Med 1975; 59: 365–72

    Article  Google Scholar 

  2. Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis: its value in present clinical practice. Ann Clin Biochem 1989; 26: 13–8

    PubMed  Google Scholar 

  3. Silverstein E, Friedland J, Pertschuk LP. Sarcoidosis pathogenesis: mechanisms of angiotensin converting enzyme elevation: epithelioid cell localization and induction in macrophages and monocytes in culture. In: Jones-Williams W, Davies BH, editors. Proceedings of 8th International Conference on sarcoidosis and other granulomatous diseases. Cardiff: Alpha and Omega Press, 1980: 246

    Google Scholar 

  4. Pertschuk LP, Silverstein E, Friedland J. Immunohistologic diagnosis of sarcoidosis: detection of angiotensin converting enzyme in sarcoid granulomas. Am J Clin Pathol 1981; 75: 350–4

    PubMed  CAS  Google Scholar 

  5. Scadding JG, Mitchell DN. Sarcoidosis. London: Chapman & Hall Medical, 1985: 181–206

    Google Scholar 

  6. Vien NK, Stahl D, Brodthagen H. Cutaneous sarcoidosis in Caucasians [abstract]. J Am Acad Dermatol 1987; 16: 534

    Article  Google Scholar 

  7. Mizuno K, Okamoto H, Horio T. Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors. Br J Dermatol 2004; 150: 205–10

    Article  PubMed  CAS  Google Scholar 

  8. Anthony F, Layton AMA. Case of cutaneous acral sarcoidosis with response to allopurinol. Br J Dermatol 2000; 142: 1052–3

    Article  Google Scholar 

  9. Claridge MW, Hobbs SD, Quick C. ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitor. Eur J Vasc Endovasc Surg 2004; 28: 67–70

    Article  PubMed  CAS  Google Scholar 

  10. Pfeffer MA, Pfeffer JM, Steinberg C. Survival after an experimental myocardial infarction: beneficial effects of long term therapy with captopril. Circulation 1985; 72: 406–12

    Article  PubMed  CAS  Google Scholar 

  11. Parmothayan S, Jones PW. Steroid therapy of sarcoidosis. JAMA 2002 Mar 13; 287 (10): 1301–7

    Article  Google Scholar 

  12. Jones E, Callen JP. Hydroxychoroquine is effective therapy for control of cutaneous sarcoidal granulomas [abstract]. J Am Acad Dermatol 1990; 23: 487–9

    Article  PubMed  CAS  Google Scholar 

  13. Webster GF, Razsi LK, Sanches M. Weekly low dose methotrexate therapy for cutaneous sarcoidosis [abstract]. J Am Acad Dermatol 1991; 24: 451–4

    Article  PubMed  CAS  Google Scholar 

  14. Carlesimo M, Giustini S, Rossi A. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866–9

    Article  PubMed  CAS  Google Scholar 

  15. Tseng S, Pak G, Washenik K. Rediscovering thalidomide: a review of its mechanism of action side effects and potential uses. J Am Acad Dermatol 1996; 35: 969–79

    Article  PubMed  CAS  Google Scholar 

  16. Cagnoni ML, Lombardi A, Cerinic MM. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995; 346 (8984): 1229–30

    Article  PubMed  CAS  Google Scholar 

  17. Yamada H, Ide A, Sugiura M. Treatment of cutaneous sarcoidosis with tranilast. J Dermatol 1995; 22 (2): 149–52

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this case report. The authors have no conflicts of interest that are directly relevant to the content of this case report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vinod Kaura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaura, V., Kaura, S.H. & Kaura, C.S. ACE Inhibitor in the Treatment of Cutaneous and Lymphatic Sarcoidosis. AM J Clin Dermatol 8, 183–186 (2007). https://doi.org/10.2165/00128071-200708030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200708030-00006

Keywords

Navigation